Supernus Pharmaceuticals (SUPN) Research & Development (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Research & Development data on file, last reported at $27.8 million in Q4 2025.

• On a quarterly basis, Research & Development fell 2.86% year-over-year to $27.8 million in Q4 2025; TTM through Dec 2025 was $106.2 million, a 2.35% decrease from a year earlier, with the FY2025 full-year figure at $106.2 million, down 2.35% from the prior year.
• Research & Development for Q4 2025 stood at $27.8 million, down from $29.4 million in the prior quarter.
• Over the last five years, Research & Development for SUPN reached as high as $29.4 million in Q3 2025 and fell as low as $15.0 million in Q1 2021.
• Historically, Research & Development has averaged $22.6 million across 5 years, with a median of $22.4 million in 2023.
• Across the five-year window, Research & Development dropped 20.79% in 2021 and jumped 48.79% in 2023, its largest moves.
• Year by year, Research & Development stood at $21.1 million in 2021, then retreated by 15.68% to $17.8 million in 2022, then jumped by 31.35% to $23.3 million in 2023, then grew by 22.7% to $28.6 million in 2024, then declined by 2.86% to $27.8 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $27.8 million in Q4 2025, $29.4 million in Q3 2025, and $22.1 million in Q2 2025.